House Amendment 224 to House Bill 987
116th Congress(2019-2020)
An amendment numbered 5 printed in House Report 116-61 to Commission a study by the National Academy of Medicine into the amount of federal funding and research used in the development of drugs by pharmaceutical companies, and to put measures in place to curb excessive drug costs.
Agreed To
Agreed to in House on May 16, 2019
Origin Chamber
House
Type
Amendment
Amendment
A proposed change to a pending text (e.g., a bill, resolution, another amendment, or a treaty [or an associated resolution of ratification]).
Amendment Number
224
Congress
116
Sort by most recent
05/16/2019
House amendment agreed to: On agreeing to the DeSaulnier amendment (A005) Agreed to by voice vote.
05/16/2019
On agreeing to the DeSaulnier amendment (A005) Agreed to by voice vote.
05/16/2019
Amendment (A005) offered by Mr. DeSaulnier. (consideration: CR H3878-3879; text: CR H3878)
05/16/2019
House amendment offered
May 16, 2019
Passed House
26
Sponsorship
Public Record
Record Updated
Feb 8, 2022 10:55:11 PM